Phaseline

Targets › PDE4B

PDE4B (3',5'-cyclic-AMP phosphodiesterase 4B): drug programs, companies and trials

17 programs from 14 companies in 64 trials: 32 Phase 2, 15 Phase 1, 11 Phase 3, 6 Phase 4; Immunology, Psychiatry, Other; next expected readout Nov 2026.

Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in mediating central nervous system effects of therapeutic agents ranging from antidepressants to antiasthmatic and anti-inflammatory agents. (UniProt, Q07343)

Open in Phaseline: the race on PDE4B, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Pennsylvania2-[18F]-FA
Voltage-gated calcium channel modulator
CHRNA4, OPRK1, OPRD1, OPRM1, UL51, ADRA2A, ADRA2C, ADRA2B, Ion channels, CACNB4, CACNB2, CACNB1, CACNB3, TNF, SLC6A4, HTR2A, HTR2C, FKBP1A, CD86, CD80, PDE4A, PDE4D, PDE4B, PDE4C, PDE3A, CHRNB2, STNPhase 4Alcohol Use Disorder; Acute Kidney Injury; Insomnia; Giant Cell Arteritis …Nov 2026
Integrative Skin Science and ResearchRoflumilast
Phosphodiesterase 4 inhibitor
PDE4A, PDE4D, PDE4B, PDE4CPhase 4ITCHAug 2027
Massachusetts General HospitalTheophylline
Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor; Adenosine receptor antagonist
PDE4A, PDE4D, PDE4B, PDE4C, PDE3APhase 4PHP IaApr 2030
Cairo UniversityCrisaborole
Phosphodiesterase 4 inhibitor
PDE4A, PDE4D, PDE4B, PDE4CPhase 3VitiligoNov 2026
Ganzhou Hemay PharmaceuticalHemay005
Phosphodiesterase 4 (PDE4) inhibitor
PDE4A, PDE4B, PDE4C, PDE4DPhase 3Behçet's Disease; Moderate to Severe Ulcerative Colitis; PsoriasisDec 2026
AmgenApremilast
Phosphodiesterase 4 inhibitor
PDE4A, PDE4D, PDE4B, PDE4CPhase 3Plaque Psoriasis; Active Juvenile Psoriatic Arthritis; Behçet Disease; Behçet's Disease …Mar 2028
Arcutis BiotherapeuticsRoflumilast
Phosphodiesterase 4 inhibitor
PDE4A, PDE4D, PDE4B, PDE4CPhase 3Atopic Dermatitis; Chronic Plaque Psoriasis; Depressive Disorder, Major; Fragile X Syndrome …Apr 2028
Merck & Co. (MSD)Ensifentrine (MK-5884)
Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor
PDE4A, PDE4D, PDE4B, PDE4C, PDE3APhase 3Pulmonary Disease, Chronic ObstructiveApr 2029
Vanderbilt University Medical CenterTheophylline
Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor; Adenosine receptor antagonist
PDE4A, PDE4D, PDE4B, PDE4C, PDE3APhase 2PseudohypoparathyroidismDec 2026
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAEnsifentrine (MK-5884)
Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor
PDE4A, PDE4D, PDE4B, PDE4C, PDE3APhase 2Pulmonary Disease, Chronic Obstructive, COPD; Non-cystic Fibrosis BronchiectasisMar 2027
Beni-Suef UniversityAminophylline
Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor; Adenosine receptor antagonist
PDE4A, PDE4D, PDE4B, PDE4C, PDE3APhase 2Acute Calculous Anuria; Pediatric Urolithiasis; Renal StonesMar 2027
MediciNovaIbudilast (MN-166)
Phosphodiesterase 4 inhibitor; Phosphodiesterase 3A inhibitor; Phosphodiesterase 10A inhibitor
PDE4A, PDE4D, PDE4B, PDE4C, PDE3APhase 2Amyotrophic Lateral SclerosisApr 2027
Medical College of WisconsinTheophylline
Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor; Adenosine receptor antagonist
PDE4A, PDE4D, PDE4B, PDE4C, PDE3APhase 1Acute Kidney InjuryMay 2027
National Institute of Mental Health (NIMH)18F-PF-06445974
PDE4B radiotracer for PET imaging
PDE4BPhase 1Alcohol Use DisorderFeb 2028
National Institute of Mental Health (NIMH)[18F]PF-06445974
PDE4B radioligand for PET imaging
PDE4BPhase 1DepressionOct 2028
National Institute of Mental Health (NIMH)[11C]ZTP-1
PDE4B imaging tracer (11C-labeled)
PDE4BPhase 1HealthyMar 2029
National Institute of Mental Health (NIMH)18F-PF974
PDE4B radiotracer for PET imaging
PDE4BPhase 1Alzheimer s DiseaseApr 2029

Conditions

Alcohol Use Disorder (7) Behçet's Disease (2) Pseudohypoparathyroidism (2) Acute Kidney Injury (2) Head and Neck Squamous Cell Carcinoma (2) Atopic Dermatitis (2) Rheumatoid Arthritis (2) Hidradenitis Suppurativa (HS) (2) Plaque Psoriasis (1) Active Juvenile Psoriatic Arthritis (1) Behçet Disease (1) Recurrent Aphtous Stomatitis (1)

Modalities

small molecule (17)

Companies

National Institute of Mental Health (NIMH) (4) Amgen (1) MediciNova (1) Beni-Suef University (1) Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA (1) Ganzhou Hemay Pharmaceutical (1) Vanderbilt University Medical Center (1) Cairo University (1) University of Pennsylvania (1) Merck & Co. (MSD) (1) Medical College of Wisconsin (1) Massachusetts General Hospital (1) Arcutis Biotherapeutics (1) Integrative Skin Science and Research (1)

Related targets

PDE4A (13) PDE4D (13) PDE4C (13) PDE3A (8) CHRNA4 (1) OPRK1 (1) OPRD1 (1) OPRM1 (1) UL51 (1) ADRA2A (1) ADRA2C (1) ADRA2B (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.